Alpha DNA Investment Management LLC Purchases New Shares in Blueprint Medicines Co. (NASDAQ:BPMC)

Alpha DNA Investment Management LLC purchased a new stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 5,098 shares of the biotechnology company's stock, valued at approximately $445,000.

Other large investors have also added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of Blueprint Medicines during the 4th quarter valued at $62,028,000. Jennison Associates LLC acquired a new position in Blueprint Medicines in the fourth quarter valued at about $31,417,000. Wellington Management Group LLP lifted its position in Blueprint Medicines by 8.0% during the fourth quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock worth $373,421,000 after purchasing an additional 316,754 shares during the period. William Blair Investment Management LLC grew its stake in Blueprint Medicines by 16.1% during the fourth quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company's stock worth $169,616,000 after buying an additional 269,896 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Blueprint Medicines in the 4th quarter valued at about $21,104,000.

Blueprint Medicines Price Performance

BPMC traded down $0.43 during trading on Thursday, reaching $85.39. 165,060 shares of the company were exchanged, compared to its average volume of 1,039,273. Blueprint Medicines Co. has a 12-month low of $73.04 and a 12-month high of $121.90. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The company has a market cap of $5.46 billion, a price-to-earnings ratio of -79.03 and a beta of 0.75. The company's 50-day moving average is $87.82 and its two-hundred day moving average is $93.12.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Research analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Jefferies Financial Group began coverage on shares of Blueprint Medicines in a research report on Monday, March 17th. They set a "buy" rating and a $135.00 price objective for the company. JMP Securities restated a "market outperform" rating and issued a $125.00 price target on shares of Blueprint Medicines in a research note on Friday, February 14th. HC Wainwright reiterated a "buy" rating and set a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th. Wolfe Research assumed coverage on Blueprint Medicines in a research note on Tuesday, March 18th. They issued an "outperform" rating for the company. Finally, Morgan Stanley assumed coverage on shares of Blueprint Medicines in a research report on Thursday, March 20th. They set an "equal weight" rating and a $100.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $124.95.

Insider Activity at Blueprint Medicines

In related news, insider Ariel Hurley sold 3,203 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the completion of the sale, the insider now directly owns 18,270 shares in the company, valued at $1,692,167.40. This represents a 14.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Christina Rossi sold 2,274 shares of the stock in a transaction on Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the sale, the chief operating officer now directly owns 69,266 shares of the company's stock, valued at $6,581,655.32. The trade was a 3.18 % decrease in their position. The disclosure for this sale can be found here. 4.21% of the stock is currently owned by insiders.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.